RATIONALE

Oncology is the leading clinical field in terms of innovation when it comes to clinical trial activity, number of companies investing in the field, amount of new therapies and diagnostic tests under development, new product launches, and level of overall expenditure.

Technology plays a key role in advancing cancer patient management in all three aspects of medicine: prevention, diagnosis and treatment. Thanks to technological innovations, physicians can make more accurate and timely diagnoses, monitor patients more thoroughly and on a more personalized basis, and employ individualized, more targeted, and less invasive new therapies. In addition, technology enables the collection of large amounts of data on patients and the effectiveness of treatments, which can be analyzed using algorithms and artificial intelligence techniques to improve clinical decision-making.

The implication is that expenditure on research and development for cancer prevention, diagnosis and treatment is a significant investment worldwide. The American Cancer Society estimates that in 2021, worldwide spending on cancer research and development was \$21.5 billion. This includes expenditure by governments, academic institutions and private corporations. Through the contributions of physicians and scientists, about 23,000 active cancer clinical trials have been registered as of March 2023, according to ClinicalTrials.gov.

At an academic level, hospitals, universities and research institutes are investing substantial resources into understanding the basic biology of cancer and in pioneering new approaches to patient care management. Service companies, the pharmaceutical industry, and biotech corporations focus their attention on developing new approaches and products to prevent, diagnose, and treat cancer.

Within both of these worlds, technological advances as well as the rise of new computational capabilities enabled by artificial intelligence, machine learning, and big data will play a significant role in the future of cancer patient care management. In 2021, a record-breaking year, more new cancer drugs became available for the first time than in any other year ever (30 new cancer active ingredients launched globally), and many of these employ new technologies to improve the way patients are treated. During this meeting we will be providing the latest updates within the field of oncology with a focus on the use of new technologies for the prevention, diagnosis, treatment, and monitoring of cancer patients. This congress will host physicians, biologists, scientists, researchers, engineers, physicists, mathematicians and other experts from relevant fields.

This panel of key national and international opinion leaders will be instrumental in representing the incredible level of innovation, discussing the latest advances in the field, exploring new possibilities for the future, and discussing the issues of equal and widespread accessibility to treatment, as well as the ethical implications related to the cost of such treatments.

SCIENTIFIC COORDINATORS GIUSEPPE CURIGLIANO MICHELINO DE LAURENTIIS

CME CREDITS

Certificate awarding 11 CME credits will be emailed within 90 days after the end of the congress. The following medical sciences have been accredited for this congress: Oncology, Radiotherapy, Pharmacists, Biology, Nurses, Pneumology, Gastroenterology, Hematology, Pathological Anatomy

EDUCATIONAL GOALS

Technical-professional contents (knowledge and skills) specific to each profession, each specialization and each ultra-specialised activity, including rare diseases and gender medicine

- SIGN UP ON WWW.OVERGROUP.EU
- PROJECT COORDINATION AND CME PROVIDER



www.overgroup.eu



THROUGHOUT THE EVENT, PHOTOS WILL BE TAKEN AND VIDEO RECORDINGS WILL BE MADE.



Unconditional Sponsorship



OG/23/0092



FACULTY

ALBINI ADRIANA Senior Scientist, IEO - Milano

Academic Research Manager At DiGiCore (Digital Institute for Cancer Outcomes REsearch) - Brussels, Belgium

ASCIERTO PAOLO ANTONIO

Head of Melanoma, Cancer Immunotherapy and Development Tharapeutics Unit, Istituto Nazionale dei Tumori IRCCS "Fondazione

Full Professor, Oncology Department, Biotec Campus Università di Torino

BIANCHINI GIAMPAOLO

Head of clinical translational and immunotherapy research Head of Breast Cancer Group "San Raffaele Hospital" - Miland

CARACCIOLO GIULIO

Professor of Applied Physics, Director of the Nanodelivery Lab, Department of Molecular Medicine, Università "Sapienza" - Roma

CHIRICO ANDREA

Researcher at the Department of Psychology of Development and Socialization, Università "Sapienza" - Roma

CINIERI SAVERIO

Head of the Medical Oncology Operational Unit San Antonio Perrino

CRISAFULLI GIOVANNI

PhD, Università di Torino and IFOM Milano

CRISCITIELLO CARMEN

Medical Oncologist, Developement of new Drugs for Innovative Therapies

CURIGLIANO GIUSEPPE

Director of Early Drug Development for Innovative Therapies Division, Co-Director of New Drug Development Program, Department of Oncology and Hemato-Oncology University of Milan, Istituto Europeo di Oncologia, Milano

DE ANGELIS CARMINE

Oncology Unit - Department of Clinical Medicine and Surgery University of Naples "Federico II" - Napoli

DE COLA LUISA

Full Professor, Università degli Studi di Milano, Director of Materials for Health at the Department of Biochemistry and Molecular Pharmacology Istituto Mario Negri - Milano

DE LAURENTIIS MICHELINO

Head of Corp-S Assistance and Cancer Treatment Department Thoracic District Istituto Nazionale dei Tumori IRCCS "Fondazione G. Pascale"-

DEL MASTRO LUCIA

Head of Complex Operative Unit, Medical Oncology Clinic Breast Unit Coordinator, IRCCS Ospedale Policlinico San Martino

DELGOFFE GREG*

Associate Professor, Department of Immunology Director, Tumor Microenvironment Center Member, Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center - Pittsburgh

Senior Research Scientist at the National Research Council of Italy, Institute for High-Performance Computing and Networking - Napoli

GENNARI ALESSANDRA

Professor of Oncology

University of Piemonte Orientale Head, Division of Oncology, AOU Maggiore della Carità - Novara

GIORDANO ANTONIO*

Head of Sbarro Institute for Cancer Research and Molecular Medicine; Co-Director of the Center for Biotechnology College of Science and

Professor at the Department of Medical Oncology, VU University Medical Center, Amsterdam; Researcher at the Pisana Foundation for Science - Pisa

GIULIANO MARIO

Associate Professor, Oncology Unit - Department of Clinical Medicine and Surgery
University of Naples "Federico II"- Napoli

GUARNERI VALENTINA

Head of Complex Operative Unit of Oncology IOV; Full Professor of Medical Oncology, Head of Postgraduate School of Medical Oncology

KAGARI TAKASHI*

Vice President - Discovery Research Laboratories I - Tokyo LAMBERTINI MATTEO

Associate Professor, Università di Genova - IRCCS Policlinico San

Martino Hospital - Genova

MAURI GIANLUCA

IFOM ETS - The AIRC Institute of Molecular Oncology - Milano Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda - Milano

Department of Oncology and Hemato-Oncology, Università degli Studi di

MELIEF CORNELIS*

Head department immunohematology Leiden (The Netherlands) University Medical Center - Leiden

NOVELLO SILVIA

Professor of Medical Oncology, Oncology Department AOU San Luigi, Università di Torino

PELLEGRINO TERESA

eam Leader Nanomaterials for Biomedical Applications, IIT Genova

PERRONE FRANCESCO Head of the Clinical trials Unit - Istituto Tumori Pascale - Napoli

PISTILLI BARBARA

Medical oncologist, Breast cancer Unit, Gustave Roussy - Villejuif

Head Of Applied Research Unit for Cognitive and Psychological Science

Director of the Department of Medical Oncology and the Medical Oncology and Oncological Prevention Unit, IRCCS CRO of Aviano, Aviano

Full Professor of Medical Oncology and Director of the Postgraduate School of Medical Oncology, University of Udine, Udine

ROLFO CHRISTIAN

Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at The Tisch Cancer Institute - New York

SIENA SALVATORE

Director Niguarda Cancer Center and professor of Medical Oncology

Director Human Longevity Program, IRCCS San Raffaele

TRAVERSO ALBERTO

Senior Staff Scientist Libera Università Vita Salute San Raffaele - Milano

TUCCINARDI TIZIANO

Professor of Pharmaceutical Chemistry at the Department of Pharmacy Università di Pisa

VALPIONE SARA

MD, PhD, Cancer Research UK Manchester Institute, The University of

VOLPE STEFANIA

Radiation Oncologist and PhD Candidate, Department of Oncology and Hemato-Oncology-University of Milan, Istituto Europeo di Oncologia

ZAMBELLI ALBERTO

Associate Professor of Oncology and Head of the Breast Cancer Section Humanitas University - IRCCS Research Hospital - Rozzano (MI)

virtual participation *

OCTOBER 9th, 2023

11:00

Opening activities G. Curigliano, M. De Laurentiis

LSESSION:

RADIOMIC PREVENTION AND BIOSENSORS

11:15 Introductory Talk A. Albini

11:35

Keynote lecture: Updates on early detection methods C. Rolfo

12:05

Technical Presentation: Radiomics and imaging of next generation S. Volpe

12:20

Technical Presentation: Digital and Al for biosensors and clinical research A. Traverso

12:35

Round Table A. Albini. G. Curigliano.

M. De Laurentiis. V. Guarneri. C. Rolfo, A. Traverso, S. Volpe

13:15 Lunch

II SESSION:

MINIMALLY INVASIVE **DIAGNOSTIC PROCEDURES AND MULTIOMICS TECHNOLOGIES**

14:30

Introductory Talk

A. Bardelli

14:50

Kevnote lecture: How liquid biopsies will change clinical practice in oncology G. Mauri

15:20

Technical Presentation: Computational Oncology: Omics analyses in circulating tumor DNA G. Crisafulli

15:35

Technical Presentation: Monitoring response to cancer imnmunomodulation in the blood S. Valpione

15:50

Round Table

A. Bardelli, S. Cinieri, G. Crisafulli G. Curigliano, M. De Laurentiis.

L. Del Mastro, M. Giuliano, G. Mauri, S. Valpione

16:30

Coffee break

III SESSION:

ADVANCED TREATMENT AND CANCER-SPECIFIC VACCINES

16:45

Introductory Talk

P. Ascierto

17:05

Kevnote lecture: What we learned from immunotherapy in the past years P. Ascierto

17:35

Technical Presentation: The role of metabolism in immunotherapy G. Delgoffe

17:50

Technical Presentation: The development of personalized cancer-specific vaccines C. Melief

18:05

Round Table P. Ascierto, G. Bianchini.

G. Curigliano, M. De Laurentiis. G. Delgoffe, A. Gennari, C. Melief,

M. Lambertini

18:45

Wrap up and take home messages G. Curigliano, M. De Laurentiis

18:55

Closing activities



OCTOBER **10th**, **2023**

9:00

Opening activities

G. Curigliano, M. De Laurentiis

9:15 - 11:05 * IV SESSION:

ANTIBODY DRUG CONJUGATE

9:15

Introductory Talk

S. Siena

9:35

Kevnote lecture: ADCs Design T. Kagari

10:05

Technical Presentation: Next Generation ADCs B. Pistilli

10:20

Technical Presentation: Biomarkers predicting activity of ADCs E. Giovannetti

10:35

Round Table

G. Curigliano, M. De Laurentiis.

E. Giovannetti, T. Kagari,

F. Perrone, B. Pistilli, S. Siena

V SESSION:

NANOMEDICINE AND **PRECISION MEDICINE**

11:05

Introductory Talk

E. Tasciotti

11:25

Kevnote lecture: Hybrid nanomaterials for targeting and killing tumors L. De Cola

11:55

Technical Presentation: Early detection and therapeutic management of cancer through the interrogation of nanoparticles' protein corona

G. Caracciolo

12:10

Technical Presentation: Internal radiotherapy based on inorganic nanoparticles

T. Pellegrino

12:25

Round Table

G. Caracciolo. C. Criscitiello

G. Curigliano, C. De Angelis, L. De Cola. M. De Laurentiis.

S. Novello, T. Pellegrino.

E. Tasciotti

12:55

Liaht Lunch

VI SESSION:

COMPUTATIONAL ONCOLOGY. AI AND VR

13:25

Introductory Talk A. Giordano

13:45

Keynote lecture: Artificial Intelligence and Virtual Reality Advances and Applications in Research Oncology and Clinical Oncology L. Gallo

14:15

Technical Presentation: Artificial Intelligence: A Modern Approach T. Tuccinardi

14:30

Technical Presentation: The benefits of virtual reality interventions for cancer patients A. Chirico

14:45

Focus On: The impact of new technologies on the care process G. Pravettoni

15:00 Round Table

A. Chirico, G. Curigliano,

M. De Laurentiis, L. Gallo, A. Giordano. G. Pravettoni.

F. Puglisi, T. Tuccinardi,

A. Zambelli

15:30

Take home messages G. Curigliano, M. De Laurentiis

15:45

Closina Activities

*Non - CMF accredited

Supporting Oncology through Innovation.